FDA Approves Merck’s ENFLONSIA™ to Prevent RSV in Infants
The Pharma Data
JUNE 9, 2025
This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season. Safety Profile and Precautions Like all biologic therapies, ENFLONSIA comes with safety considerations.
Let's personalize your content